Multi-target tyrosine kinase inhibitor nanoparticle delivery systems for cancer therapy

Mater Today Bio. 2022 Jul 12:16:100358. doi: 10.1016/j.mtbio.2022.100358. eCollection 2022 Dec.

Abstract

Multi-target Tyrosine Kinase Inhibitors (MTKIs) have drawn substantial attention in tumor therapy. MTKIs could inhibit tumor cell proliferation and induce apoptosis by blocking the activity of tyrosine kinase. However, the toxicity and drug resistance of MTKIs severely restrict their further clinical application. The nano pharmaceutical technology based on MTKIs has attracted ever-increasing attention in recent years. Researchers deliver MTKIs through various types of nanocarriers to overcome drug resistance and improve considerably therapeutic efficiency. This review intends to summarize comprehensive applications of MTKIs nanoparticles in malignant tumor treatment. Firstly, the mechanism and toxicity were introduced. Secondly, various nanocarriers for MTKIs delivery were outlined. Thirdly, the combination treatment schemes and drug resistance reversal strategies were emphasized to improve the outcomes of cancer therapy. Finally, conclusions and perspectives were summarized to guide future research.

Keywords: Cancer treatment; Combination therapy; Drug delivery; Drug resistance; Multi-target tyrosine kinase inhibitors.

Publication types

  • Review